UCB SA UCBJY
Set alert
As of Nov 2, 3:47 PM ET
- YTD
- +11.53%
- 1 year
- +21.26%
- Open
- 157.00
- Prev close
- 156.80
- Mkt cap
- 59.34B
- Vol
- 2.06K
- Avg vol
- 48.80K
- EPS
- 6.60
- P/E
- 23.62
More statistics
- Low
- 155.36
- High
- 157.00
- Earnings
- Feb 25, 2027
News
1 week ago benzinga.com
What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
MoonLake stock rallies after AbbVie HS data misses competitor benchmarks, reinforcing sonelokimab's competitive positioning ahead of 2027 launch plans.
3 weeks ago seekingalpha.com
UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript
UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript
1 month ago defenseworld.net
UCB (OTCMKTS:UCBJY) Reaches New 1-Year Low – Should You Sell?
UCB SA (OTCMKTS:UCBJY - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday. The company traded as low as $116.29 and last traded at $116.38, with a volume of 6770…
1 month ago seekingalpha.com
UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
1 month ago seekingalpha.com
UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
1 month ago zacks.com
UCB (UCBJY) Upgraded to Buy: Here's Why
UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 months ago zacks.com
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
2 months ago defenseworld.net
UCB (OTCMKTS:UCBJY) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?
Shares of UCB SA (OTCMKTS:UCBJY - Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $145.86 and traded as low as $122.54.…
3 months ago seekingalpha.com
UCB SA (UCBJY) Q2 2026 Earnings Call Transcript
UCB SA (UCBJY) Q2 2026 Earnings Call Transcript
3 months ago defenseworld.net
UCB SA (OTCMKTS:UCBJY) Short Interest Down 60.4% in July
UCB SA (OTCMKTS:UCBJY - Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 2,283 shares, a drop of 60.4%…
4 months ago seekingalpha.com
UCB SA (UCBJY) Analyst/Investor Day Transcript
UCB SA (UCBJY) Analyst/Investor Day Transcript
6 months ago zacks.com
UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know
UCB (UCBJY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
8 months ago reuters.com
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1…
8 months ago seekingalpha.com
UCB SA (UCBJY) Q4 2025 Earnings Call Transcript
UCB SA (UCBJY) Q4 2025 Earnings Call Transcript
9 months ago benzinga.com
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
9 months ago seekingalpha.com
UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10 months ago benzinga.com
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.
10 months ago defenseworld.net
Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis
UCB (OTCMKTS:UCBJY - Get Free Report) and Minerva Neurosciences (NASDAQ: NERV - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses…
10 months ago defenseworld.net
UCB (OTCMKTS:UCBJY) Share Price Crosses Above 50 Day Moving Average – What’s Next?
UCB SA (OTCMKTS:UCBJY - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $137.71 and traded as high as…
11 months ago benzinga.com
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline
Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, raising concerns for next-generation tau-targeting drug programs.
1 year ago zacks.com
Recent Price Trend in UCB (UCBJY) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, UCB (UCBJY) could be a great choice. It is one of the several stocks that passed through our "Recent Price…
1 year ago zacks.com
UCB (UCBJY) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, UCB (UCBJY) could be a great choice. It is one of the several stocks that passed through our "Recent Price…
1 year ago zacks.com
All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy
UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).